Skip to main content

Loading market data...

HAE

Haemonetics Corporation

NYSE • United states

$118.21

-$0.52

(-0.44%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Management
Credibility
Score

Haemonetics Corporation (HAE)

Unavailable

Quotes may be delayed

$5.38B

Market Cap

583,879

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Haemonetics Corporation Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 125 SUMMER STREET, BOSTON, MA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

8 Oct 2026

Haemonetics Corporation reported Regulation FD disclosure

Haemonetics Corporation filed an 8-K covering Regulation FD disclosure.

18 Aug 2026

Haemonetics Corporation reported Regulation FD disclosure

Haemonetics Corporation filed an 8-K covering Regulation FD disclosure.

12 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Haemonetics Corporation.

7 Aug 2026

Haemonetics Corporation securities registration filing

Haemonetics Corporation filed a registration or prospectus document concerning securities.

6 Aug 2026

Haemonetics Corporation filed Form 10-Q

Haemonetics Corporation submitted Form 10-Q to the SEC for the period ending Jun 27, 2026.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$223.38M

Total assets (USD)$2.37B

Shareholders' equity (USD)$837.10M

Long-term debt (USD)$1.17B

Debt due within a year (USD)$4.96M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 27 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$339.38M	$57.46M	$33.01M	$0.72	10-Q · 6 Aug 2026
Q4 2025	$338.97M	$67.40M	$44.74M	$0.95	10-Q · 5 Feb 2026
Q3 2025	$327.32M	$58.49M	$38.68M	$0.81	10-Q · 6 Nov 2025
Q2 2025	$321.39M	$53.87M	$34.03M	$0.70	10-Q · 7 Aug 2025
Q4 2024	$348.54M	$59.03M	$37.49M	$0.74	10-Q · 6 Feb 2025
Q3 2024	$345.51M	$51.70M	$33.83M	$0.66	10-Q · 7 Nov 2024

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $125.38

6.1% upside potential

📈

Strong Buy

Unavailable

👍

Buy

7

⏸️

Hold

2

📉

Sell

0

9 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 11:49 UTC Targets range 86.00–140.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

24

Jul 2026

Madaus Martin D

Director

Grant or award

Unavailable per share

2,538 shares

24

Jul 2026

Zane Ellen M

Director

Grant or award

Unavailable per share

2,538 shares

24

Jul 2026

Pomeroy Claire

Director

Grant or award

Unavailable per share

2,538 shares

24

Jul 2026

KROLL MARK W

Director

Grant or award

Unavailable per share

2,538 shares

24

Jul 2026

Johnson Lloyd Emerson

Director

Grant or award

Unavailable per share

2,538 shares

24

Jul 2026

COYLE MICHAEL J

Director

Grant or award

Unavailable per share

2,538 shares

24

Jul 2026

Bryant Diane M

Director

Grant or award

Unavailable per share

2,538 shares

24

Jul 2026

ABERNATHY ROBERT E

Director

Grant or award

Unavailable per share

2,538 shares

Top Shareholders

Blackrock, Inc.

5,909,258 shares

5.147% change

6/30/2026

Vanguard Group Inc

4,761,135 shares

-1.521% change

12/31/2025

Neuberger Berman Group Llc

4,179,443 shares

17.37% change

6/30/2026

Vanguard Portfolio Management Llc

2,546,394 shares

-0.505% change

6/30/2026

Aqr Capital Management Llc

2,266,489 shares

-32.475% change

6/30/2026

Ariel Investments, Llc

2,060,966 shares

New% change

6/30/2026

Vanguard Capital Management Llc

2,059,578 shares

-1.474% change

6/30/2026

State Street Corp

1,818,186 shares

2.554% change

6/30/2026

Dimensional Fund Advisors Lp

1,585,222 shares

19.544% change

6/30/2026

Citadel Advisors Llc

1,510,120 shares

484.971% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 11:49 UTC· 18 hours ago

Research coverage and investment tools

Haemonetics Corporation (HAE) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Medical/Dental Instruments). Its last price was US$118.21 on 20 Oct 2026. That is 93% of the way from its 52-week low of US$48.98 to its 52-week high of US$123.77. Its market capitalisation was US$5.38 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$339.38M	$57.46M	$33.01M	$0.72	59.8%	16.9%	$44.42M	10-Q · 6 Aug 2026 (opens in a new tab)
Q4 2025	$338.97M	$67.40M	$44.74M	$0.95	59.7%	19.9%	—	10-Q · 5 Feb 2026 (opens in a new tab)
Q3 2025	$327.32M	$58.49M	$38.68M	$0.81	59.5%	17.9%	—	10-Q · 6 Nov 2025 (opens in a new tab)
Q2 2025	$321.39M	$53.87M	$34.03M	$0.70	59.8%	16.8%	$13.64M	10-Q · 7 Aug 2025 (opens in a new tab)
Q4 2024	$348.54M	$59.03M	$37.49M	$0.74	55.5%	16.9%	—	10-Q · 6 Feb 2025 (opens in a new tab)
Q3 2024	$345.51M	$51.70M	$33.83M	$0.66	54.2%	15.0%	—	10-Q · 7 Nov 2024 (opens in a new tab)

Cash and equivalents: $223.38M
Total assets: $2.37B
Shareholders' equity: $837.10M
Long-term debt: $1.17B
Debt due within a year: $4.96M

8-K · 8 Oct 2026

Haemonetics Corporation reported Regulation FD disclosure (opens in a new tab)

Haemonetics Corporation filed an 8-K covering Regulation FD disclosure.
8-K · 18 Aug 2026

Haemonetics Corporation reported Regulation FD disclosure (opens in a new tab)

Haemonetics Corporation filed an 8-K covering Regulation FD disclosure.
SCHEDULE 13G/A · 12 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Haemonetics Corporation.
S-8 · 7 Aug 2026

Haemonetics Corporation securities registration filing (opens in a new tab)

Haemonetics Corporation filed a registration or prospectus document concerning securities.
10-Q · 6 Aug 2026

Haemonetics Corporation filed Form 10-Q (opens in a new tab)

Haemonetics Corporation submitted Form 10-Q to the SEC for the period ending Jun 27, 2026.

Insider	Date	Transaction	Shares	Average price	Filing
Madaus Martin D Director	24 Jul 2026	Grant or award (A)	+2,538	—	Form 4 (opens in a new tab)
Zane Ellen M Director	24 Jul 2026	Grant or award (A)	+2,538	—	Form 4 (opens in a new tab)
Pomeroy Claire Director	24 Jul 2026	Grant or award (A)	+2,538	—	Form 4 (opens in a new tab)
KROLL MARK W Director	24 Jul 2026	Grant or award (A)	+2,538	—	Form 4 (opens in a new tab)
Johnson Lloyd Emerson Director	24 Jul 2026	Grant or award (A)	+2,538	—	Form 4 (opens in a new tab)
COYLE MICHAEL J Director	24 Jul 2026	Grant or award (A)	+2,538	—	Form 4 (opens in a new tab)
Bryant Diane M Director	24 Jul 2026	Grant or award (A)	+2,538	—	Form 4 (opens in a new tab)
ABERNATHY ROBERT E Director	24 Jul 2026	Grant or award (A)	+2,538	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	5,909,258	5.147%
Vanguard Group Inc	12/31/2025	4,761,135	-1.521%
Neuberger Berman Group Llc	6/30/2026	4,179,443	17.37%
Vanguard Portfolio Management Llc	6/30/2026	2,546,394	-0.505%
Aqr Capital Management Llc	6/30/2026	2,266,489	-32.475%
Ariel Investments, Llc	6/30/2026	2,060,966	New
Vanguard Capital Management Llc	6/30/2026	2,059,578	-1.474%
State Street Corp	6/30/2026	1,818,186	2.554%
Dimensional Fund Advisors Lp	6/30/2026	1,585,222	19.544%
Citadel Advisors Llc	6/30/2026	1,510,120	484.971%

Previous close: 118.73 USD
Day range: 117.25 – 120.48 USD
52-week range: 48.98 – 123.77 USD
Volume: 583,879
Market cap: $5.38B
Average volume: 647,393
EPS (FY 2025, diluted): 2.05 USD
Shares outstanding: 45.50M
Beta (5Y monthly): 0.61

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:10 UTC· 22 minutes ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for HAE yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.